2022年急性髓系白血病分类在真实世界环境中的适用性
该研究基于1001例急性髓系白血病(AML)患者,按WHO 2022、ICC 2022和ELN 2022重新分类,评估真实世界适用性。WHO 2016与WHO 2022及ICC分类的总体诊断变化率分别为22.8%和23.7%,ICC与WHO 2022间患者分布差异13.1%。2022年分类改善了诊断方案,常规细胞遗传学仍对56%的继发性AML保持强大诊断作用。
要点
- 1001例AML患者重新分类后,WHO 2016与WHO 2022及ICC的总体诊断变化率分别为22.8%和23.7%。
- ICC与WHO 2022间患者分布差异为13.1%。
- 常规细胞遗传学对56%的继发性AML仍保持强大诊断作用。
核心结论
- 2022年AML分类在真实世界中显著改善了诊断方案,WHO与ICC诊断方案存在相似性,有必要尝试生成统一模型。
研究设计与样本
- 对1001例诊断为AML的患者基于新分类方案进行重新分类的真实世界研究。
主要发现
- WHO 2016与WHO 2022及ICC分类的总体诊断变化率分别为22.8%和23.7%。
- ICC与WHO 2022间患者分布差异为13.1%。
- ICC的“非特指型”和WHO的“按分化定义”AML类别规模较WHO 2016缩小(分别为24.1%和26.8% vs 38.7%),主要因骨髓增生异常(MDS)相关组扩大。
- 397例ICC定义的MDS相关AML患者中,55.9%通过MDS相关核型定义。
- ELN 2017与ELN 2022间总体重新分层率为12.9%。
临床怎么用
- 常规细胞遗传学通常可快速获得且较分子特征检测便宜,在真实世界中仍对继发性AML保持强大的诊断作用。
- 鉴于WHO与ICC诊断方案的相似性,作者认为尝试生成统一模型是可取的。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The increasing knowledge of molecular genetics of acute myeloid leukemia (AML) necessitated the update of previous diagnostic and prognostic schemes, which resulted in the development of the World Health Organization (WHO), the International Consensus Classification (ICC), and the new European LeukemiaNet (ELN) recommendations in 2022. We aimed to provide a real-world application of the new models, unravel differences and similarities, and test their implementation in clinical AML diagnosis. A total of 1001 patients diagnosed with AML were reclassified based on the new schemes. The overall diagnostic changes between the WHO 2016 and the WHO 2022 and ICC classifications were 22.8% and 23.7%, respectively, with a 13.1% difference in patients' distribution between ICC and WHO 2022. The 2022 ICC "not otherwise specified" and WHO "defined by differentiation" AML category sizes shrank when compared with that in WHO 2016 (24.1% and 26.8% respectively, vs 38.7%), particularly because of an expansion of the myelodysplasia (MDS)-related group. Of 397 patients with a MDS-related AML according to the ICC, 55.9% were defined by the presence of a MDS-related karyotype. The overall restratification between ELN 2017 and ELN 2022 was 12.9%. The 2022 AML classifications led to a significant improvement of diagnostic schemes. In the real-world setting, conventional cytogenetics, usually rapidly available and less expensive than molecular characterization, stratified 56% of secondary AML, still maintaining a powerful diagnostic role. Considering the similarities between WHO and ICC diagnostic schemes, a tentative scheme to generate a unified model is desirable.
引用
- Attardi E, Savi A, Borsellino B, et al. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv. 2023. PMID: 37327116. doi:10.1182/bloodadvances.2023010173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。